Navigation Links
Low levels of PYY hormone a very early indicator of type 2 diabetes
Date:3/10/2008

It may soon be possible to take a simple blood test and predict whether or not someone has low levels of a particular molecule, predisposing them to the development of Type 2 diabetes. If the test is positive, it may then be possible to use preventative treatment, slowing down, or even halting that development.

Such is the hope of scientists and clinicians at Sydneys Garvan Institute of Medical Research who have shown conclusively that people who produce low levels of the molecule PYY have a higher risk of developing Type 2 diabetes and obesity.

The findings were published online on 4 March in the prestigious International Journal of Obesity.

It is already known that the hormone PYY, which is released from the gut after a meal, creates a feeling of satiety. When PYY is in oversupply, it prevents diet-induced obesity in mice.

Professor Herbert Herzog, Director of Garvans Neuroscience Program, and an expert on appetite, says that the new findings are important in that they show a metabolic defect before the presence of any disease or manifestation of weight gain. We can now see that low PYY levels after eating are a very early predictor of the development of obesity and Type 2 diabetes, he said.

Professor Lesley Campbell, Director of Diabetes Services at St. Vincents Hospital and a senior member of Garvans Diabetes and Obesity Clinical Studies group, has been researching genetic factors in the development of Type 2 diabetes for over 10 years. Specifically, her research looks at people before they get the disease, the contributing factors, and the effects of the diabetes.

Professor Campbell has already published findings that insulin resistant people, with a family history of Type 2 diabetes, have low levels of PYY. In earlier studies we hinted at the fact that before any of the abnormalities of diabetes are present, people already have an abnormality of satiety, marked by the lack of the secretion of this PYY hormone, she said.

We now have published that, even earlier in the development of diabetes, people who are not yet insulin resistant show a low secretion of PYY. They have a blunted post-meal secretion of this hormone, making them less likely to feel satiety, and more likely to gain weight.

Professor Campbells research involved elaborate testing of two groups of people, eight in each group, over a period of two years. One group had relatives with Type 2 diabetes, the other group had no family history of the disease. The groups were matched for gender, for age and for adiposity.

It was most important to match the groups for their fatness, said Professor Campbell. The only difference was their relatives. You assume that they are carrying the genetic burden of diabetes, which we already know to be a reality.

Low levels of PYY at this very early pre-diabetes stage could be used as a marker, or predictor, that Type 2 diabetes is very likely to develop.

As a clinician, I am hopeful that it will be possible to screen extensively in the future, and therefore stem the spread of this debilitating disease.


'/>"/>

Contact: Alison Heather
A.heather@garvan.org.au
61-292-958-128
Research Australia
Source:Eurekalert

Related medicine news :

1. Estrogen Levels in Blood Predict Breast Cancers Return
2. Atypical protein kinase C stabilizes SRC-3 levels in breast cancer cells
3. Moderate Aerobic Fitness Levels May Cut Stroke Risk
4. Novel link between excessive nutrient levels and insulin resistance
5. Silymarin does not affect virus activity or ALT levels in
6. In Unfolding Budget Debate, Alliance to Spotlight Flawed MedPAC Policy Guidance, Failure to Evaluate Medicaid Margins in Recommending Medicare Funding Levels
7. New findings show Enbrel significantly reduced levels of C-reactive protein
8. Low vitamin E levels associated with physical decline in elderly
9. High Levels of Stress After 9/11 Raised Heart Disease Risk
10. College Drinking Games Lead to Higher Blood Alcohol Levels
11. Tis the Season to be Jolly ... and Stress-Free: Survey Reveals Womens Stress Levels During the Holidays
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... Gensuite ... Brilliance Awards under the Best New Product Launch category. Gensuite’s entry on their ... experience. , BOC Global Events & Training Group is a professional event and ...
(Date:12/7/2016)... ... December 07, 2016 , ... “The Road To Restoration”: an ... not a one hour a week showing of hands. “The Road To Restoration” is ... “Perhaps you are familiar with the brass ring that you could reach out for, ...
(Date:12/7/2016)... , ... December 07, 2016 , ... “Fred Rides a ... Christmas Day that follows. , “Fred Rides a Train” is the creation of ... short stories since her teen years in Michigan. The "Fred, the Dog" series is ...
(Date:12/7/2016)... ... 2016 , ... Dr. Greg Leyer, the Chief Scientific Officer ... DC workshop on November 2nd. The conference was an opportunity for both probiotic ... regulations. , Dr. Leyer spoke about two main topics at the IPA ...
(Date:12/6/2016)... ... 06, 2016 , ... People with Parkinson’s disease and cognitive ... type of MRI, according to a study appearing online in the journal Radiology. ... characterized by tremors or trembling and stiffness in the limbs, impaired balance and ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... Dec. 6, 2016 Eurofins Genomics today ... the College of American Pathologists (CAP) and certification ... its new laboratory in Louisville, KY ... North American headquarters. "Our new CLIA-licensed ... which is still considered the ,Gold Standard, method ...
(Date:12/6/2016)... WESTLAKE VILLAGE, Calif. , Dec. 6, ... a privately held, clinical-stage medical dermatology and ... Creabilis plc, a privately held specialty pharmaceutical ... for common inflammatory skin conditions, including psoriasis, ... terms of the agreement, Sienna will make ...
(Date:12/6/2016)... 2016  Regulus Therapeutics Inc. (NASDAQ: ... and development of innovative medicines targeting microRNAs, today ... R&D day, held in New York ... anti-miR targeting microRNA-27 (miR-27) for the treatment of ... anti-miR targeting microRNA-17 (miR-17) for the treatment of ...
Breaking Medicine Technology: